Efficacy evaluation of axitinib/axitinib

Axitinib/Axitinib is a new oral multi-target tyrosine kinase inhibitor, mainly used for the treatment of advanced renal cell carcinoma. Its main mechanism of action is to prevent tumor angiogenesis and growth by inhibiting vascular endothelial growth factor receptors 1, 2 and 3. Axitinib has shown good efficacy in the treatment of advanced renal cell carcinoma.

Axitinib was compared with sorafenib in a pivotal study of723 patients with advanced renal cell carcinoma. These patients were previously treated with other cancer drugs (such as sunitinib or cytokine therapy) without response. The main evaluation criterion of the study is how long patients survive without tumor progression. The results showed that the average progression-free survival of patients taking axitinib was 6.7 months, compared with 4.7 months in the sorafenib group. The results of the study show that axitinib is significantly more effective than sorafenib in the treatment of advanced renal cancer, especially in patients who have received cytokine therapy.

In addition, in phase III clinical trials in patients with metastatic renal cell carcinoma, axitinib also showed a high objective response rate and significantly prolonged progression-free survival. This result makes axitinib the first targeted drug to confirm its effectiveness in second-line treatment in a phase III prospective randomized trial, providing a new treatment option for patients with advanced renal cell carcinoma, especially those who have poor response to other therapies.

Although axitinib is generally well tolerated, there are concerns regarding its unique pattern of adverse events. Common adverse reactions include diarrhea, high blood pressure, fatigue, nausea and vomiting. Although the incidence of grade 3 or 4 toxicity is low, the medical team still needs to closely monitor the patient's health status to manage and adjust the treatment plan in a timely manner.

In summary, axitinib has demonstrated significant efficacy in the treatment of advanced renal cell carcinoma and provides patients with a more flexible treatment strategy. At the same time, patients need to be vigilant about potential adverse reactions.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/23357974/